Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | PHASE1 | RECRUITING | 154 | — | — | Apr 1, 2025 | Jan 1, 2028 | Apr 6, 2026 | 30 | United States, Taiwan |
| Arm | Type | Description |
|---|---|---|
| Cohort A - Arm A1: CHS-114 Dose A + Toripalimab | EXPERIMENTAL | Participants will be treated with dose A of CHS-114 administered as an intravenous (IV) infusion in combination with toripalimab every 3 weeks (Q3W). |
| Cohort A - Arm A2: CHS-114 Dose B + Toripalimab | EXPERIMENTAL | Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab Q3W. |
| Cohort B - Arm B1: CHS-114 Dose A + Toripalimab | EXPERIMENTAL | Participants will be treated with dose A of CHS-114 administered as an IV infusion in combination with toripalimab Q3W. |
| Cohort B - Arm B2: CHS-114 Dose B + Toripalimab | EXPERIMENTAL | Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab Q3W. |
| Cohort C - Arm C: CHS-114 Dose B + Toripalimab + 5 fluorouracil (5 FU) + Cisplatin | EXPERIMENTAL | Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab, 5 FU, and cisplatin Q3W. |
| Experimental: Cohort D - Arm D1 (Liver Mets): CHS-114 + Toripalimab | EXPERIMENTAL | Participants will be treated with CHS-114 administered as an IV infusion in combination with toripalimab Q3W. |
| Experimental: Cohort D - Arm D2 (Non-Liver Mets): CHS-114 + Toripalimab | EXPERIMENTAL | Participants will be treated with CHS-114 administered as an IV infusion in combination with toripalimab Q3W. |
| Name | Type | Description |
|---|---|---|
| CHS-114 | DRUG | Solution for infusion |
| Toripalimab | DRUG | Solution for infusion |
| 5 Fluorouracil | DRUG | Solution for infusion |
| Cisplatin | DRUG | Solution for infusion |
Key Inclusion Criteria: * At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator. * Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v5.0...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |